CurveBeam AI Limited (ASX:CVB): Orthopaedic CT Imaging and Bone Health Technology

Aditi Sarkar

12 October 2026 05:44 PM AEDT

CurveBeam AI Limited (ASX:CVB): Orthopaedic CT Imaging and Bone Health Technology

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

CurveBeam AI develops point-of-care computed tomography equipment for orthopaedic care.
HiRise provides weight-bearing imaging for assessment of lower-extremity anatomy.
OssView software is focused on evaluating bone microarchitecture from high-resolution images.
H1 FY26 Revenue reached $4.96m, while the company reported a net loss.
Commercial execution depends on device adoption, regulatory requirements and funding.

CurveBeam AI Limited (ASX:CVB) develops and manufactures specialised cone-beam computed tomography (CT) equipment for orthopaedic imaging, supported by software for clinical visualisation and bone assessment. Its devices are designed for use at or near the point of care, including specialist practices and outpatient settings. The company’s 2026 financial disclosures and product portfolio illustrate the connection between equipment sales, clinical adoption and ongoing Investment in diagnostic technology.

How HiRise and Other Imaging Systems Work

The HiRise system captures three-dimensional images of the lower extremities, including examinations conducted while patients bear weight. That capability gives clinicians a view of bone and joint alignment under load, which can differ from non-weight-bearing assessment. CurveBeam AI (ASX:CVB) also offers equipment for extremity scans and associated image visualisation tools.

The commercial model involves placing imaging systems with healthcare providers. Adoption therefore depends on clinical workflow, available facilities and purchasing decisions. Device installations and orders are distinct from revenue recognised in a reporting period, making the timing of delivery and acceptance relevant when interpreting results.

OssView and the Bone Health Programme

OssView analyses high-resolution CT images of the distal radius to assess aspects of bone microarchitecture. This separates its intended bone health application from the company’s established orthopaedic imaging equipment. CurveBeam AI (ASX:CVB) identifies OssView as investigational in the United States and states that it is not FDA-cleared or available for US sale.

The distinction is important: technical functionality, clinical evidence, regulatory clearance and commercial availability represent different stages of medical technology development. Future product claims must be assessed against the relevant approved indications and available clinical data.

Financial Performance in H1 FY26

For the half-year covered by its February 2026 reporting, CurveBeam AI (ASX:CVB) disclosed revenue of $4.96m and a loss from ordinary activities after tax of $9.85m. It reported an operating loss of $6.65m and net cash used in Operating Activities of $6.33m. These figures show that expenditure remained above recognised revenue during the period.

Cash at the end of H1 FY26 was A$4.02m. The company also described further cash receivable from existing purchase orders in its release. Cash receipts, recognised sales and operating losses are different measures, so each provides a separate view of the company’s financial position.

Commercial Factors and Operational Risks

For CurveBeam AI (ASX:CVB), hospital and specialist-clinic Capital budgets are relevant to the sales cycle. Procurement reviews, installation requirements, clinical Training and equipment servicing can influence how quickly a device order translates into routine use. Competition from other imaging technologies and the cost of maintaining product development are additional considerations.

The company’s imaging and software operations also involve distinct regulatory obligations. A cleared scanner does not automatically imply clearance for every related software function. Continuing research, testing, software development and Manufacturing activity can require funding before additional products generate revenue.

Key Insights

CurveBeam AI (ASX:CVB) combines weight-bearing orthopaedic CT imaging with a developing software-based approach to bone assessment. Its H1 FY26 results show commercial revenue alongside operating losses and cash expenditure. The central Business considerations are equipment adoption, product-specific regulatory status and the relationship between cash resources and operating commitments.

FAQs

Q: What does CurveBeam AI manufacture?

A:It develops specialised cone-beam CT scanners for orthopaedic and extremity imaging.

Q: What is HiRise used for?

A:HiRise supports three-dimensional assessment of lower-extremity anatomy, including weight-bearing scans.

Q: What is OssView designed to assess?

A:It analyses high-resolution CT images to examine bone microarchitecture.

Q: Is OssView approved for sale in the United States?

A:The company describes OssView as investigational and not FDA-cleared for US sale.

Q: What were the reported H1 FY26 revenue and net loss?

A:Revenue was $4.96m and the loss from ordinary activities after tax was $9.85m.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.